THOMASVILLE REGIONAL MEDICAL CENTER
1. Target Overview & Investment Thesis
THOMASVILLE REGIONAL MEDICAL CENTER is a 29-bed under-performing / distressed in CLARKE, AL with $6.5M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 49.4% Medicare, 32.7% Medicaid, and 17.9% commercial.
Thesis: Turnaround. Our ML models identify $489K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -145.0% (+752bps).
| Net Revenue HCRIS | $6.5M |
| Current EBITDA COMPUTED | $-9.9M |
| Operating Margin COMPUTED | -100.0% |
| Occupancy HCRIS | 4.0% |
| Revenue / Bed COMPUTED | $224K |
| Net-to-Gross HCRIS | 14.9% |
| Distress Probability ML | 65.8% |
2. Market Context & Competitive Position
AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -100.0% places it below the state median. Among 56 size-comparable peers (14-58 beds), the median margin is -14.8%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (14-58), prioritizing same-state peers. 56 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| THOMASVILLE REGIONAL MEDICAL C (Target) | AL | 29 | $6.5M | -100.0% |
| RUSSELL MEDICAL CENTER | AL | 45 | $75.3M | -14.8% |
| JACK HUGHSTON MEMORIAL HOSPITA | AL | 47 | $75.2M | 6.5% |
| NORTH BALDWIN INFIRMARY | AL | 35 | $55.3M | -3.3% |
| PRATTVILLE BAPTIST HOSPITAL | AL | 55 | $53.5M | -16.2% |
| HIGHLANDS MEDICAL CENTER | AL | 45 | $45.9M | -30.2% |
| ST. VINCENTS ST. CLAIR | AL | 40 | $40.8M | 8.7% |
| TROY REGIONAL MEDICAL CENTER | AL | 41 | $39.0M | -9.1% |
| WHITFIELD REGIONAL HOSPITAL | AL | 47 | $38.7M | -21.3% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $489K (752bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $137K | +210bp | 18mo |
| Denial Rate Reduction | 12.0% | 6.5% | $133K | +205bp | 12mo |
| Cost to Collect | 4.5% | 2.5% | $130K | +200bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $79K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $10K | +15bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-9.9M |
| + RCM Uplift | +$489K |
| Pro Forma EBITDA | $-9.4M |
| Current Margin | -100.0% |
| Pro Forma Margin | -145.0% |
| WC Released (1x) | $249K |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-15.3M | $-60.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-15.3M | $-71.6M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-13.7M | $-74.9M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-13.7M | $-85.8M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-16.8M | $-58.0M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-16.8M | $-69.3M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (32.7%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| Medium | Low occupancy | At 4.0%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 65.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 56 hospitals with 14-58 beds
- Same-state prioritization (n=57)
- Comp margins: P25=-25.6% / P50=-14.8% / P75=-2.4%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.